Trevi Therapeutics Inc. to Release Q1 2025 Earnings Update

Trevi Therapeutics, Inc., a pharmaceutical company based in New Haven, United States, is set to release its first-quarter 2025 financial results on May 8, 2025. The company, which operates within the Health Care sector, specializes in developing treatments such as nalbuphine ER for chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia. Trevi Therapeutics provides health care services primarily for patients residing in the United States.

As of the latest available data, Trevi Therapeutics’ stock price closed at $6.9 USD on an unspecified date. Over the past year, the company’s stock has experienced significant fluctuations, with a 52-week low of $2.3 USD recorded on June 9, 2024, and a 52-week high of $7.39 USD achieved on March 9, 2025. The most recent close price, as of May 5, 2025, was $6.58 USD.

The company’s market capitalization stands at approximately $702 million USD. However, its valuation metrics present a complex picture. The price-to-earnings ratio is currently at -14.67, reflecting challenges in profitability or accounting for significant research and development expenses. Additionally, the price-to-book ratio is 6.48, suggesting a higher market valuation relative to its book value.

Trevi Therapeutics trades on the Nasdaq stock exchange, and investors and stakeholders can find more information about the company’s activities and offerings on its website, www.trevitherapeutics.com .

As the company prepares to release its Q1 earnings, investors are keenly watching for updates on its financial performance and strategic developments in its pipeline of treatments.